Business Description
Actinium Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00507W1071
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 42.41 | |||||
Equity-to-Asset | 0.5 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.57 | |||||
Beneish M-Score | -2.91 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | -27.8 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.21 | |||||
9-Day RSI | 69.19 | |||||
14-Day RSI | 62.56 | |||||
6-1 Month Momentum % | 84.12 | |||||
12-1 Month Momentum % | -2.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 10.59 | |||||
Quick Ratio | 10.59 | |||||
Cash Ratio | 10.42 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.4 | |||||
Shareholder Yield % | -10.54 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -61645.68 | |||||
Net Margin % | -57346.91 | |||||
FCF Margin % | -49660.81 | |||||
ROE % | -99.21 | |||||
ROA % | -50.51 | |||||
ROIC % | -1304.62 | |||||
ROC (Joel Greenblatt) % | -1669.66 | |||||
ROCE % | -59.79 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2986.67 | |||||
PB Ratio | 6.01 | |||||
Price-to-Tangible-Book | 6.02 | |||||
EV-to-EBIT | -3.7 | |||||
EV-to-Forward-EBIT | -3.47 | |||||
EV-to-EBITDA | -3.76 | |||||
EV-to-Forward-EBITDA | -3.47 | |||||
EV-to-Revenue | 2281.3 | |||||
EV-to-Forward-Revenue | 4408.15 | |||||
EV-to-FCF | -4.65 | |||||
Price-to-Net-Current-Asset-Value | 6.44 | |||||
Price-to-Net-Cash | 6.65 | |||||
Earnings Yield (Greenblatt) % | -27.03 | |||||
FCF Yield % | -14.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Actinium Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.074 | ||
EPS (TTM) (€) | -1.582 | ||
Beta | -0.37 | ||
Volatility % | 71.66 | ||
14-Day RSI | 62.56 | ||
14-Day ATR (€) | 0.41237 | ||
20-Day SMA (€) | 7.29875 | ||
12-1 Month Momentum % | -2.88 | ||
52-Week Range (€) | 3.58 - 8.75 | ||
Shares Outstanding (Mil) | 29.78 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Actinium Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Actinium Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Actinium Pharmaceuticals Inc Frequently Asked Questions
What is Actinium Pharmaceuticals Inc(STU:7AY1)'s stock price today?
When is next earnings date of Actinium Pharmaceuticals Inc(STU:7AY1)?
Does Actinium Pharmaceuticals Inc(STU:7AY1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |